Ultimately, a deeper understanding of whether IL-17 acts more as a friend or foe in gastric cancer could lead to more effective, personalized therapeutic strategies tailored to the unique profiles of gastric cancer patients, integrating the distinct inflammatory contexts influencing disease progression. This evidence concerns the gene IL17A and gastric cancer.